

CORPORATE OVERVIEW

Kashiv BioSciences, founded in 2011, has evolved into a premier, fully integrated biopharmaceutical company offering next-generation drug delivery technologies, specialty pharmaceutical products, and affordable biosimilars. We target clinical unmet needs of patients suffering from orphan, chronic, and debilitating diseases to improve efficacy, safety, affordability, and overall quality of life.

After acquiring a biosimilar company in 2019, Kashiv has transformed into a fully integrated biosciences company with capabilities in both development and manufacturing of small and large molecules. We plan to commercialize our products via strategic partnerships and, for select products, through the creation of an internal specialized Sales & Marketing organization.

LEADERSHIP

The company's scientific and business executives have extensive industry experience in developing advanced drug delivery technologies, making novel products, and creating high-value enterprises. Kashiv is led by a successful entrepreneur, Chintu Patel, who co-founded and built Amneal Pharmaceuticals, the fifth largest generic pharmaceutical company in the United States.

BUSINESS UNITS

Kashiv has four key business units: advanced drug delivery technologies for internal drug development and strategic partnering; a large pipeline of differentiated 505(b)(2) NDA products; biosimilar development and manufacturing; and R&D of prodrugs that significantly improve the performance of known molecules.

DRUG DELIVERY

Next-generation technologies for improved oral drug delivery

- GRANDE™ – gastric retention systems
- KRONOTEC™ – timed release technology
- R&D Center in Bridgewater, NJ

BIOSIMILARS

Fully Integrated Development Infrastructure

- Products in late-stage development
- Mammalian and Microbial Platforms
- R&D and Manufacturing Facilities in Chicago, IL, Piscataway, NJ & Gujarat, India

505(b)(2) PRODUCTS

Portfolio of Differentiated Products in Clinical Development

- Orals
- Injectables
- Development and Manufacturing in Bridgewater, NJ & Gujarat, India

PRODRUGS

- Initial targets are known drugs requiring improved safety and efficacy
- Lead candidates in preclinical development
- New state-of-the-art R&D center in Gujarat, India

BRIDGEWATER

995 US HWY 202/206
BRIDGEWATER, NJ 08807
908.895.1520

PISCATAWAY

20 NEW ENGLAND AVENUE
PISCATAWAY, NJ 08854
732.475.0500

CHICAGO

3440 S. DEARBORN ST.
CHICAGO, IL 60616
312.620.1500

INDIA

FP 27/2, 43, TP-85, BLOCK-B,
OPP. APPLEWOODS TOWNSHIP
S P RING ROAD, AHMEDABAD
382210, GUJARAT, INDIA